On Dec. 12, 2012, deCODE genetics announced an agreement whereby Amgen acquired deCODE Genetics, a global leader in human genetics, headquartered in Reykjavik, Iceland. The all-cash transaction values deCODE Genetics at $415 million.

Founded in 1996, deCODE Genetics is a global leader in analyzing and understanding the link between the genome and disease susceptibility. Using its unique expertise and access to a well-defined population in Iceland, deCODE Genetics has discovered genetic risk factors for dozens of diseases ranging from cardiovascular disease to cancer.